Early-Stage Alzheimer’s Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways

Evidence for brain glucose dysregulation in Alzheimer's disease

(2018) Yang An et al.   Alzheimers & Dementia

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

(2018) Christopher H. van Dyck   BIOLOGICAL PSYCHIATRY

The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson’s Disease

(2018) David C. Schöndorf et al.   Cell Reports

Systematic Literature Review and Meta-Analysis of Diagnostic Test Accuracy in Alzheimer's Disease and Other Dementia Using Autopsy as Standard of Truth

(2018) Sandrine Cure et al.   JOURNAL OF ALZHEIMERS DISEASE

Long-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes

(2018) Tze Pin Ng et al.   JOURNAL OF ALZHEIMERS DISEASE

Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines

(2018) Brian R. Ott et al.   Frontiers in Aging Neuroscience

Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy

(2017) Peter M LoCoco et al.   eLife

Intranasal Insulin Administration Dose-Dependently Modulates Verbal Memory and Plasma Amyloid-β in Memory-Impaired Older Adults

(2017) Mark A. Reger et al.   JOURNAL OF ALZHEIMERS DISEASE

Epidemiological Trends Strongly Suggest Exposures as Etiologic Agents in the Pathogenesis of Sporadic Alzheimer's Disease, Diabetes Mellitus, and Non-Alcoholic Steatohepatitis

(2017) Suzanne M. de la Monte et al.   JOURNAL OF ALZHEIMERS DISEASE

Neuroprotective Efficacy of an Aminopropyl Carbazole Derivative P7C3-A20 in Ischemic Stroke

(2016) Shu-Na Wang et al.   CNS Neuroscience & Therapeutics

Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer’s Disease

(2016) Suzanne M. de la Monte   DRUGS

Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology

(2016) Antonella Tramutola et al.   Expert Review of Neurotherapeutics

Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer’s Disease

(2016) Suzanne M. de la Monte et al.   JOURNAL OF ALZHEIMERS DISEASE

The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond

(2016) A. L. João et al.   Obesity Reviews

Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies

(2016) James Yarmolinsky et al.   Scientific Reports

A Syntenic Cross Species Aneuploidy Genetic Screen Links RCAN1 Expression to β-Cell Mitochondrial Dysfunction in Type 2 Diabetes

(2016) Heshan Peiris et al.   PLoS Genetics

Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology

(2016) Antonella Tramutola et al.   Expert Review of Neurotherapeutics

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

(2015) Kirsten L. Viola et al.   ACTA NEUROPATHOLOGICA

Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective

(2015) Piotr Lewczuk et al.   Advances in Medical Sciences

Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease

(2015) Robert Baranello et al.   Current Alzheimer Research

Targeting Insulin Signaling for the Treatment of Alzheimer's Disease

(2015) Yanxing Chen et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Nampt/PBEF/Visfatin Exerts Neuroprotective Effects Against Ischemia/Reperfusion Injury via Modulation of Bax/Bcl-2 Ratio and Prevention of Caspase-3 Activation

(2015) Sohaila Erfani et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment

(2015) Xiaohua Li et al.   Clinical Interventions in Aging

Biological markers of Alzheimer?s disease

(2014) Leonardo Cruz de Souza et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Brain metabolic dysfunction at the core of Alzheimer's disease

(2014) Suzanne M. de la Monte et al.   BIOCHEMICAL PHARMACOLOGY

Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain

(2014) D. Allan Butterfield et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

White Matter Hypoperfusion and Damage in Dementia: Post-Mortem Assessment

(2014) Seth Love et al.   BRAIN PATHOLOGY

Extracellular Visfatin has Nicotinamide Phosphoribosyltransferase Enzymatic Activity and is Neuroprotective Against Ischemic Injury

(2014) Yan Zhao et al.   CNS Neuroscience & Therapeutics

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease

(2014) Mirjana Babić et al.   CROATIAN MEDICAL JOURNAL

Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review

(2014) Suzanne M. de la Monte   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Neuronal NAMPT is Released after Cerebral Ischemia and Protects against White Matter Injury

(2014) Zheng Jing et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Amyloid-ß-directed immunotherapy for Alzheimer's disease

(2014) L. Lannfelt et al.   JOURNAL OF INTERNAL MEDICINE

Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer’s disease

(2014) Natalia N. Nalivaeva et al.   Frontiers in Aging Neuroscience

Visfatin is involved in TNFα-mediated insulin resistance via an NAD+/Sirt1/PTP1B pathway in 3T3-L1 adipocytes

(2014) Erwan Gouranton et al.   Adipocyte

Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

(2013) Jessica Freiherr et al.   CNS DRUGS

Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art

(2013) Suzanne M de la Monte   Expert Opinion on Drug Delivery

Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease

(2012) Suzanne M. de la Monte   Current Alzheimer Research

Intranasal Insulin Suppresses Food Intake via Enhancement of Brain Energy Levels in Humans

(2012) K. Jauch-Chara et al.   DIABETES

Increased Expression of the Glucose-Responsive Gene,RCAN1, Causes Hypoinsulinemia, β-Cell Dysfunction, and Diabetes

(2012) Heshan Peiris et al.   ENDOCRINOLOGY

Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

(2012) Konrad Talbot et al.   JOURNAL OF CLINICAL INVESTIGATION

Clinical Validation of 18F-AZD4694, an Amyloid- -Specific PET Radioligand

(2012) Z. Cselenyi et al.   JOURNAL OF NUCLEAR MEDICINE

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

(2012) Adam S Fleisher et al.   LANCET NEUROLOGY

Plasminogen Activator Inhibitor-1 and Thrombotic Cerebrovascular Diseases

(2012) Anna Tjärnlund-Wolf et al.   STROKE

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway

(2011) Pei Wang et al.   ANNALS OF NEUROLOGY

Insulin resistance and Alzheimer's disease

(2011) Suzanne M. De La Monte   BMB Reports

Insulin resistance and pathological brain ageing

(2011) B. Cholerton et al.   DIABETIC MEDICINE

Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimerʼs Disease

(2011) Suzanne M. de la Monte   DRUGS

si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder

(2011) Suzanne M de la Monte et al.   Molecular Brain

Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?

(2010) Nigel Irwin et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Immunotherapy for Alzheimer’s disease

(2010) D. Morgan   JOURNAL OF INTERNAL MEDICINE

Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer’s brain

(2010) Suqing Wang et al.   JOURNAL OF NEUROCHEMISTRY

Visfatin, glucose metabolism and vascular disease: a review of evidence

(2010) Pedro Saddi-Rosa et al.   Diabetology & Metabolic Syndrome

Neprilysin and Insulin-Degrading Enzyme Levels Are Increased in Alzheimer Disease in Relation to Disease Severity

(2009) James Scott Miners et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

INTRANASAL INSULIN IMPROVES COGNITION AND MODULATES  -AMYLOID IN EARLY AD

(2009) M. S. Dhamoon et al.   NEUROLOGY

Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial

(2008) H Schmidt et al.   JOURNAL OF MEDICAL GENETICS

Dietary intervention in older adults with early-stage Alzheimer Dementia: Early lessons learned

(2008) B. Shatenstein et al.   Journal of Nutrition Health & Aging